Product Description
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Myelodysplastic Syndrome|Polycythemia Vera|Myeloproliferative Disorders|Myelofibrosis|Preleukemia|Thrombocythemia, Essential|Acute Myeloid Leukemia|Prostate Cancer|Sarcoma
Phase 1: Tobacco Use Disorder|Healthy Volunteers|Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Leukemia|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRO 33922 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-05-05 |
|
| MEI-011 | P2 |
Terminated |
Preleukemia|Myelodysplastic Syndrome |
2020-12-01 |
24% |
| PRAN-16-52 | P3 |
Terminated |
Acute Myeloid Leukemia |
2020-08-20 |
|
| 2016-004724-34 | N/A |
Terminated |
Acute Myeloid Leukemia |
2020-07-02 |